UNSPSC 51282129: Faropenem medoxomil

This classification denotes a beta-lactam antibiotic C17H19NO8S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5OK523O4FU, chemically known as (5-methyl-2-oxo-1,3-dioxoren-4-yl)methyl(5r,6s)-6-((r)-1-hydroxyethyl)-7-oxo-3-((r)-2-tetrahydrofuryl)-4-thia-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylate, but more generally known as faropenem medoxomil, which bears US NIH Compound Identifier 6918218. Most nations, for tariff and trade purposes, schedule faropenem medoxomil under HS 29419000 and SITC 54139.

As of Q4 2014, FAROPENEM MEDOXOMIL remains US FDA's Preferred Term for this commodity. Faropenem medoxomil bears US NLM identifiers UMLS ID C1880735 and NCI Concept Code C65621. SMILES: CC1C(OC(=O)O1)COC(=O)C2=C(S[C@H]3N2C(=O)[C@@H]3[C@@H](C)O)[C@H]4CCCO4.

UNSPSC 51282129 Faropenem medoxomil is a Commodity code for a specific antibiotic pharmaceutical product, but recent state and local procurement activity under this code shows minimal relevant solicitation volume. The two most recent records in the tracking system do not align with faropenem medoxomil procurement: one documents an Illinois Department of Public Health piggyback pharmaceutical contract (completed in August 2026) for Doxycycline Hyclate and Ciprofloxacin Hydrochloride tablets through the MMCAP Infuse consortium, totaling $2,999,999.11 over three years, and the other records a Seminole County, Florida procurement (posted June 2026) for Naloxone and Safe Drug Deactivation Systems. Neither opportunity involves faropenem medoxomil.

The source does not report active open solicitations, awarded contracts, or issuing-body patterns specifically for faropenem medoxomil at the state and local level. The tagged records appear to reflect general pharmaceutical procurement rather than narrow-spectrum antibiotic sourcing. Without evidence of recent or sustained state and local demand for this specific pharmaceutical commodity, the code presents limited pursuit signals at this time.